<DOC>
	<DOC>NCT01008813</DOC>
	<brief_summary>A 1-year multicenter, randomized, single-blinded, phase II trial, stratified on HAART. The purpose of this trial is to evaluate the immunogenicity and safety of a A(H1N1)French National Agency for Research on AIDS and Viral Hepatitis influenza vaccine, administered with or without adjuvant, in HIV-infected patients after one or two injections.</brief_summary>
	<brief_title>Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age ≥ 18 years Able to give written consent Covered by French Social Security HIVinfected (infection attested by the patient's chart) Patients treated by HAART for at least 6 months, with a viral load inferior to 50 copies/mL on at least 2 last visits Patients without any treatment for HIV for at least 6 months and without any indication to start a treatment in the following 3 months Patients followed for their HIVinfection in an ANRS center and whose home is close to the center in case of influenzalike illness, consultation and hospitalization in the center where he is followed if necessary For women with childbearing potential, using an effective method of contraception, and willing to undergo urine pregnancy tests prior to each vaccination. Pregnancy Receipt of chemotherapy, immunotherapy (IL2, IL7, IV Ig), or corticosteroids within 3 months prior to enrolment Thrombopenia inferior to 20 000/mm3 Febrile episode (at least 38°C rectal or if at least 37,5°C measured orally) within one week prior to vaccination Opportunistic infection (treated for less than 1 month) Coinfection with HCV and treated with IFNa Influenza (clinically or virologically documented) in the last 6 months History of documented autoimmune disease (lupus, systemic inflammatory disease, ...) Child C cirrhosis Solid organ transplant recipient Intolerance to 1 component of the vaccine Other immunization received within 3 weeks prior to inclusion or planned until after the last vaccine injection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>adjuvanted and non-adjuvanted A(H1N1)v influenza vaccine</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
</DOC>